AU2009218456A1 - Combination comprising a cannabinoid receptor binding compound and an opioid - Google Patents

Combination comprising a cannabinoid receptor binding compound and an opioid Download PDF

Info

Publication number
AU2009218456A1
AU2009218456A1 AU2009218456A AU2009218456A AU2009218456A1 AU 2009218456 A1 AU2009218456 A1 AU 2009218456A1 AU 2009218456 A AU2009218456 A AU 2009218456A AU 2009218456 A AU2009218456 A AU 2009218456A AU 2009218456 A1 AU2009218456 A1 AU 2009218456A1
Authority
AU
Australia
Prior art keywords
pain
combination
alkyl
receptor binding
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009218456A
Other languages
English (en)
Inventor
Thomas George Evans
Donald Johns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009218456A1 publication Critical patent/AU2009218456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009218456A 2008-02-28 2009-02-26 Combination comprising a cannabinoid receptor binding compound and an opioid Abandoned AU2009218456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08152104 2008-02-28
EP08152104.9 2008-02-28
PCT/EP2009/052297 WO2009106574A2 (en) 2008-02-28 2009-02-26 Combinations for treating hiv-associated pain

Publications (1)

Publication Number Publication Date
AU2009218456A1 true AU2009218456A1 (en) 2009-09-03

Family

ID=39415383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009218456A Abandoned AU2009218456A1 (en) 2008-02-28 2009-02-26 Combination comprising a cannabinoid receptor binding compound and an opioid

Country Status (11)

Country Link
US (1) US20090281194A1 (https=)
EP (1) EP2257281A2 (https=)
JP (1) JP2011513278A (https=)
KR (1) KR20100126441A (https=)
CN (1) CN101945650A (https=)
AU (1) AU2009218456A1 (https=)
BR (1) BRPI0907805A2 (https=)
CA (1) CA2716405A1 (https=)
EA (1) EA201001363A1 (https=)
MX (1) MX2010009507A (https=)
WO (1) WO2009106574A2 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB0012795D0 (en) * 2000-05-25 2000-07-19 Novartis Ag Organic compounds
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US20090029984A1 (en) * 2005-07-11 2009-01-29 N.V. Organon Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)

Also Published As

Publication number Publication date
MX2010009507A (es) 2010-09-24
EA201001363A1 (ru) 2011-04-29
JP2011513278A (ja) 2011-04-28
BRPI0907805A2 (pt) 2015-07-14
WO2009106574A2 (en) 2009-09-03
CN101945650A (zh) 2011-01-12
WO2009106574A3 (en) 2009-12-17
CA2716405A1 (en) 2009-09-03
US20090281194A1 (en) 2009-11-12
EP2257281A2 (en) 2010-12-08
KR20100126441A (ko) 2010-12-01

Similar Documents

Publication Publication Date Title
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
JP5751831B2 (ja) 鎮痛耐性抑制剤
JP2014196328A (ja) ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤
JP2015512425A (ja) チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
AU2025279727A1 (en) Combinations of opioids and N-acylethanolamines
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
CA2892578C (en) Pharmaceutical combinations of a pck inhibitor and a mek inhibitor for use in treatment of cancer
US20240342156A1 (en) Methods for treating pain
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
AU2009218456A1 (en) Combination comprising a cannabinoid receptor binding compound and an opioid
CA3245251A1 (en) TREATMENT METHOD COMPRISING KRAS G12C INHIBITORS AND SHP2 INHIBITORS
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
AU2004233582B2 (en) Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
EP1797883A2 (en) Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
CA3259252A1 (en) CANCER POLYTHERAPY INCLUDING AN FLT3 INHIBITOR
WO2003059355A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
JP2009510158A (ja) 毒物依存症の治療におけるネボグラミンの使用
NZ786609A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
WO2005039593A1 (en) Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application